Search for a Writer:
Calculated Writer Scores
- Frequency of opinion markers: Not set
- Sentiment markers: Not set
- What is this?
Community Writer Scores
Coverage
Words Associated with DOUGLAS CRESS
Most Frequently Mentioned Topics
Sources They're Writing For (last 60 days)
Writer Feed Widget
Grab this free widget and get the latest news for this writer. You can post it on your web page or blog, or add it to your desktop. Click on the "get & share" button at the bottom.
Articles Written by: DOUGLAS CRESS
Onyx Pharmaceuticals (ONXX) has agreed to purchase private biotechnology company Proteolix for $276 million in cash, Bloomberg reports. The acquisition will provide Onyx with a late-stage, next-generation therapy to treat multiple myeloma, a form of ...
From DOUGLAS CRESS,
Seeking Alpha,
13 Oct 2009
It’s been nothing but sunshine and roses for the company, which is now considering a $98 million buyout from hedge fund Elliott Associates. Endologix has received two new FDA clearances in as many weeks, further positioning the company for long term ...
From DOUGLAS CRESS,
ETF Investor,
24 Oct 2008
Kinetic Concepts (KCI) has received FDA 510[k] clearance for its LifeCell Tissue Matrix. The matrix is used to treat chronic, trauma, surgical and other acute wounds. The product utilizes the company’s Strattice technology, a sterile reconstructive ...
From DOUGLAS CRESS,
ETF Investor,
16 Oct 2008
While true, by most measures, AngioDynamics' (ANGO) first quarter was a resounding success.
Net sales were $44.3 million, an 18% increase year-over-year. Gross margins rose to 61.9% compared with 60.0% in the same period last year. Operating income ...
From DOUGLAS CRESS,
Seeking Alpha,
5 Oct 2008
In a move that could accelerate the growth of Clarient’s biomarker business, the company announced Friday that, with Definiens, it will develop and commercialize tools to help evaluate quantitative biomarkers that predict cancer treatment ...
From DOUGLAS CRESS,
ETF Investor,
30 Sep 2008
Thermage (THRM) has received an unsolicited takeover bid from an as-yet-unnamed third party calling for the acquisition of all outstanding shares at $5.50 a piece. That bid, to be paid in cash or a combination of cash and stock (it appears to be a ...
From DOUGLAS CRESS,
Seeking Alpha,
21 Aug 2008
Device giant Medtronic (MDT) Sofamor Danek has filed a complaint against NuVasive (NUVA), alleging patent infringement by certain NuVasive products.
NuVasive is in the process of reviewing the complaint and assessing its defenses. Based on an initial ...
From DOUGLAS CRESS,
Seeking Alpha,
20 Aug 2008
Despite the slowdown seen in the aesthetics market, second quarter revenue at Thermage (THRM) totaled $17.9 million, a 2% increase over Q2 2007. International revenue increased 10 percent while domestic revenues declined four percent.
The company ...
From DOUGLAS CRESS,
Seeking Alpha,
13 Aug 2008
I’d like to think my call to action was responsible for this quarter’s promising results:
Retractable reported revenue of $6.5 million in the three months ended June 30, 2008.Unit sales increased 29.9% year-over-year.Domestic revenue increased 12.7% ...
From DOUGLAS CRESS,
Seeking Alpha,
13 Aug 2008
Not wanting to break a winning streak, Clarient (CLRT) delivered its 16th consecutive quarter of quarterly revenue growth. The company posted revenues of $16.9 million in its most recent quarter, a 71% increase over the same period last year.
Based on ...
From DOUGLAS CRESS,
ETF Investor,
11 Aug 2008
